RealTimeTouch.com RealTimeTouch.com Patent US9639150 RealTimeTouch.com message RealTimeTouch.com RealTimeTouch.com



new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)




RealTimeTouch.com RealTimeTouch.com Patent US9639150 RealTimeTouch.com message RealTimeTouch.com RealTimeTouch.com
  

Alexion Pharmaceuticals Inc patents

Recent patent applications related to Alexion Pharmaceuticals Inc. Alexion Pharmaceuticals Inc is listed as an Agent/Assignee. Note: Alexion Pharmaceuticals Inc may have other listings under different names/spellings. We're not affiliated with Alexion Pharmaceuticals Inc, we're just tracking patents.

ARCHIVE: New 2017 2016 2015 2014 2013 2012 2011 2010 2009 | Company Directory "A" | Alexion Pharmaceuticals Inc-related inventors




Date Alexion Pharmaceuticals Inc patents (updated weekly) - BOOKMARK this page
06/22/17 new patent  Compositions and methods for treating craniosynostosis
06/01/17High concentration formulations of anti-c5 antibodies
05/25/17Npp1 fusion proteins
03/16/17Recombinant glycosylated eculizumab and eculizumab variants
01/26/17Atypical hemolytic uremic syndrome (ahus) biomarker proteins
01/19/17Methods for treating complement-associated disorders
01/19/17Treatment of paroxysmal nocturnal hemoglobinuria patients by an inhibitor of complement
12/29/16Treatment of paroxysmal nocturnal hemoglobinuria patients by an inhibitor of complement
12/29/16Anti-c5a antibodies
12/08/16Production of transgenic avians using improved retroviral vectors
12/08/16Methods for treating complement-associated disorders
12/08/16Methods for treating complement-associated disorders
11/03/16Methods and compositions for treating complement-associated disorders
09/22/16High concentration formulations of anti-c5 antibodies
09/15/16Nucleic acids encodng anti-c5a antibodies
09/01/16Anti-c5 antibodies having improved pharmacokinetics
08/25/16Treatment of paroxysmal nocturnal hemoglobinuria patients by an inhibitor of complement
07/28/16High concentration formulations of anti-c5 antibodies
07/21/16Anti-c5a antibodies
06/30/16Treatment of graft rejection by administering a complement inhibitor to an organ prior to transplant
06/23/16Methods of purifying recombinant proteins
06/16/16Method for treating a complement mediated disorder caused by an infectious agent in a patient
06/09/16Anti-c5a antibodies
06/02/16Atypical hemolytic uremic syndrome (ahus) biomarker proteins
05/19/16Risk evaluation and management strategy involving patient follow-ups relating to the use or discontinuation of a complement inhibitor
04/21/16Methods of shifting an isoelectric profile of a protein product and uses thereof
04/21/16Methods of replicating a large scale eculizumab production cell culture
04/21/16Anti-c5 antibodies having improved pharmacokinetics
04/21/16Methods of culturing a cell
02/25/16Compositions and methods for increasing the serum half-life of a therapeutic agent targeting complement c5
02/25/16Bone delivery conjugates and using same to target proteins to bone
02/25/16Nucleic acides encoding anti-c5a antibodies
02/04/16Biomarkers of immunomodulatory effects in humans treated with anti-cd200 antibodies
01/14/16Therapeutic methods using anti-cd200 antibodies
12/24/15Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
10/22/15Anti-c5 antibodies having improved pharmacokinetics
09/03/15Screening assays for complement component c5 antagonists
07/02/15Anti-c5a antibodies and methods for using the antibodies
06/25/15Compositions comprising a complement inhibitor and an interferon alpha inhibitor
06/18/15Humaneered anti-factor b antibody
03/19/15Atypical hemolytic uremic syndrome biomarker proteins
01/01/15Rationally designed antibodies
09/25/14Reagents and methods for detecting pnh type ii white blood cells and their identification as risk factors for thrombotic disorders
07/24/14Antibodies having reduced immunogenicity in a human
06/19/14Use of an anti-cd200 antibody for prolonging the survival of allografts
02/27/14High concentration antibody formulations
10/17/13Polypeptides that bind to human complement component c5
09/19/13Methods of distributing complement-inhibiting drugs to patients receiving a complement inhibitor
08/29/13Anti-c5a antibodies and methods for using the antibodies
07/25/13Therapeutic methods using anti-cd200 antibodies
07/04/13Antibodies to ox-2/cd200 and uses thereof
06/20/13Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
03/14/13Methods and compositions for treating degos' disease
02/21/13Reagents and methods for detecting pnh type ii white blood cells and their identification as risk factors for thrombotic disorders
12/20/12Antibodies to ox-2/cd200 and uses thereof in inhibiting immune responses
12/06/12Method of treating hemolytic disease
09/20/12Treatment of paroxysmal nocturnal hemoglobinuria patients by an inhibitor of complement
09/13/12High concentration antibody formulations
09/06/12Methods and compositions for treating complement-associated disorders
06/14/12Antibodies to ox-2/cd200 and uses thereof
05/03/12Method of treating autoimmune disease by inducing antigen presentation by tolerance inducing antigen presenting cells
03/22/12Antibodies containing therapeutic tpo/epo mimetic peptides
12/22/11Engineered antibodies with reduced immunogenicity and methods of making
09/29/11Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
09/22/11Hybrid antibodies
Patent Packs
06/09/11Chronic lymphocytic leukemia cell line
04/14/11Method of treating hemolytic disease
01/27/11Hybrid antibodies
01/27/11Diagnosis and treatment of blood disorders
01/06/11Bispecific antibodies that bind to complement proteins
11/18/10Antibodies to ox-2/cd200 and uses thereof in inhibiting immune responses
11/11/10Antibodies to ox-2/cd200 and uses thereof
09/23/10Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
08/05/10Methods and compositions for treating autoimmune disease
06/10/10Methods and compositions for the treatment of antibody mediated neuropathies
06/03/10Prolongation of survival of an allograft by inhibiting complement activity
03/25/10Hybrid antibodies
03/18/10Method of treating hemolytic disease
02/18/10Rationally designed antibodies
09/03/09Treatment of paroxysmal nocturnal hemoglobinuria patients by an inhibitor of complement
Patent Packs
05/21/09Rationally designed antibodies
03/19/09Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof







ARCHIVE: New 2017 2016 2015 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Alexion Pharmaceuticals Inc in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Alexion Pharmaceuticals Inc with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###




';